207 related articles for article (PubMed ID: 23356032)
21. Comparison of PCR mediated amplification of DNA and the classical methods for detection of Mycobacterium leprae in different types of clinical samples in leprosy patients and contacts.
Torres P; Camarena JJ; Gomez JR; Nogueira JM; Gimeno V; Navarro JC; Olmos A
Lepr Rev; 2003 Mar; 74(1):18-30. PubMed ID: 12669929
[TBL] [Abstract][Full Text] [Related]
22. Fixed-duration multidrug therapy in multibacillary leprosy.
Li HY; Hu LF; Wu PW; Luo JS; Liu XM
Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):230-7. PubMed ID: 9251596
[TBL] [Abstract][Full Text] [Related]
23. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
[TBL] [Abstract][Full Text] [Related]
24. Patient profile and treatment satisfaction of Brazilian leprosy patients in a clinical trial of uniform six-month multidrug therapy (U-MDT/CT-BR).
Ferreira IP; Buhrer-Sékula S; De Oliveira MR; Gonçalves Hde S; Pontes MA; Penna ML; Cruz R; Penna GO
Lepr Rev; 2014 Dec; 85(4):267-74. PubMed ID: 25675651
[TBL] [Abstract][Full Text] [Related]
25. Epidemiological characteristics of leprosy reactions: 15 years experience from north India.
Kumar B; Dogra S; Kaur I
Int J Lepr Other Mycobact Dis; 2004 Jun; 72(2):125-33. PubMed ID: 15301592
[TBL] [Abstract][Full Text] [Related]
26. Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients.
Cellona RV; Balagon MF; dela Cruz EC; Burgos JA; Abalos RM; Walsh GP; Topolski R; Gelber RH; Walsh DS
Int J Lepr Other Mycobact Dis; 2003 Dec; 71(4):308-19. PubMed ID: 14763888
[TBL] [Abstract][Full Text] [Related]
27. Are 18 doses of WHO/MDT sufficient for multibacillary leprosy; results of a trial in Malawi.
Pönnighaus JM; Boerrigter G
Int J Lepr Other Mycobact Dis; 1995 Mar; 63(1):1-7. PubMed ID: 7730703
[TBL] [Abstract][Full Text] [Related]
28. World Health Organization (WHO) antibiotic regimen against other regimens for the treatment of leprosy: a systematic review and meta-analysis.
Lazo-Porras M; Prutsky GJ; Barrionuevo P; Tapia JC; Ugarte-Gil C; Ponce OJ; Acuña-Villaorduña A; Domecq JP; De la Cruz-Luque C; Prokop LJ; Málaga G
BMC Infect Dis; 2020 Jan; 20(1):62. PubMed ID: 31959113
[TBL] [Abstract][Full Text] [Related]
29. Leprosy beyond MDT: study of follow-up of 100 released from treatment cases.
Vara N; Agrawal M; Marfatia Y
Indian J Lepr; 2010; 82(4):189-94. PubMed ID: 21434595
[TBL] [Abstract][Full Text] [Related]
30. Pattern of bacillary clearance in multibacillary leprosy patients with multidrug therapy.
Kumar A; Girdhar A; Girdhar BK
Acta Leprol; 2003; 12(3):123-8. PubMed ID: 15040703
[TBL] [Abstract][Full Text] [Related]
31. Incidence of late lepra reaction among multibacillary leprosy patients after MDT.
Vijayakumaran P; Manimozhi N; Jesudasan K
Int J Lepr Other Mycobact Dis; 1995 Mar; 63(1):18-22. PubMed ID: 7730714
[TBL] [Abstract][Full Text] [Related]
32. Impairments in multibacillary leprosy; a study from Brazil.
Pimentel MI; Nery JA; Borges E; Gonçalves RR; Sarno EN
Lepr Rev; 2004 Jun; 75(2):143-52. PubMed ID: 15282965
[TBL] [Abstract][Full Text] [Related]
33. Ocular hypotension and hypotony in multibacillary leprosy patients; at diagnosis, during and after completion of multidrug therapy.
Daniel E; Rao PS; Ffytche TJ; Courtright P
Indian J Lepr; 2010; 82(4):181-8. PubMed ID: 21434594
[TBL] [Abstract][Full Text] [Related]
34. New lesions after MDT in PB and MB leprosy: a report of 28 cases.
Kar HK; Sharma P
Indian J Lepr; 2008; 80(3):247-55. PubMed ID: 19432355
[TBL] [Abstract][Full Text] [Related]
35. Two microbiological relapses in a patient with lepromatous leprosy.
Chakma JK; Girdhar A; Natrajan M; Kumar A; Girdhar BK
Lepr Rev; 2008 Sep; 79(3):331-4. PubMed ID: 19009984
[TBL] [Abstract][Full Text] [Related]
36. Effect of corticosteroid usage combined with multidrug therapy on nerve damage assessed using nerve conduction studies: a prospective cohort study of 365 untreated multibacillary leprosy patients.
Capadia GD; Shetty VP; Khambati FA; Ghate SD
J Clin Neurophysiol; 2010 Feb; 27(1):38-47. PubMed ID: 20087206
[TBL] [Abstract][Full Text] [Related]
37. Disabilities in multibacillary leprosy following multidrug therapy with and without immunotherapy with Mycobacterium w antileprosy vaccine.
Sharma P; Kar HK; Misra RS; Mukherjee A; Kaur H; Mukherjee R; Rani R
Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):250-8. PubMed ID: 10575404
[TBL] [Abstract][Full Text] [Related]
38. Risk factors for erythema nodosum leprosum.
Manandhar R; LeMaster JW; Roche PW
Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):270-8. PubMed ID: 10575406
[TBL] [Abstract][Full Text] [Related]
39. Long-term follow up of multibacillary leprosy patients with high BI treated with WHO/MDT regimen for a fixed duration of two years.
Shaw IN; Natrajan MM; Rao GS; Jesudasan K; Christian M; Kavitha M
Int J Lepr Other Mycobact Dis; 2000 Dec; 68(4):405-9. PubMed ID: 11332283
[TBL] [Abstract][Full Text] [Related]
40. Comparative evaluation of immunotherapeutic efficacy of BCG and mw vaccines in patients of borderline lepromatous and lepromatous leprosy.
Narang T; Kaur I; Kumar B; Radotra BD; Dogra S
Int J Lepr Other Mycobact Dis; 2005 Jun; 73(2):105-14. PubMed ID: 16830653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
